html { overflow: visible; height: auto; } .MainNav_ItemWrapper:hover .Subnavigation_Wrapper, .MainNav_Item:focus + .Subnavigation_Wrapper { display: block; } .Header-FixedHeight .Dialoog, .Header-FixedHeight .Title_Wrapper, .Accordion_ContentContainer.Hidden { height: auto !important; visibility: visible; } .Dialoog_Step.Invisible, .Title_Wrapper.Invisible, main.Invisible, .js-GridItem { transform: none; opacity: 1; } .Dialoog_Form, .js-OptionsOpenBtn, .Image_Wrapper-Scaled, .Video_Wrapper-Scaled, img[data-src] { display: none; } .js-MasonryGrid { display: flex; flex-wrap: wrap; }

CYP11B1-CYP11B2 - glucocorticoid-remediable aldosteronism (GRA)

This test is available for the following conditions:

Conditions > Endocrine > Glucocorticoid Remediabel Aldosteronism
Conditions > Renal / Nephrological > Glucocorticoid Remediabel Aldosteronism

Turnaround time
Complete analysis: 8 weeks / Targeted analysis: 4 weeks

Method

PCR followed by fragment (length) analysis

Remarks
Glucocorticoid-remediable aldosteronism is caused by a fusion of the CYP11B1 and CYP11B2 genes. This is the only described mutation in glucocorticoid-remediable aldosteronism (Lifton et al, 1992, Nature, 355: 262).

OMIM: 124080
Performing laboratory: Radboudumc
Authorized material(s): EDTA blood, Isolated DNA, Buccal mucous membrane

GEN

complete analysis

targeted analysis of a familial mutation

€ 327

Add Update Remove

Go to main content